The metabolic improvements associated with GLP-1 agonist use, including better glucose control and weight management, may indirectly contribute to improved brain health
These effects are seen even outside of diabetes control.[ref] Decreased colon cancer mortality: A 5-year mortality study in colon cancer patients showed that GLP-1 RA use decreased mortality risk by 60% in obese patients.[ref] Decreased risk of substance abuse: A large 2026 study using data from the VA showed that GLP-1 RA drugs reduce the risk of developing a substance addiction (drugs, alcohol)
Its toxicity is linked to excessive Production of ROS, resulting in oxidative damage and inflammation in the inner ear
Adding electrolytes can also help if fatigue comes with lightheadedness
The 2025 SEMALEAN study, which tracked 106 patients on semaglutide 2.4 mg using DXA body composition scans over 12 months, confirmed that semaglutide does cause some lean mass loss alongside fat loss a pattern seen with virtually all significant caloric restriction
ensure the product's integrity
